Abstract
Asbestos is a general term for a heterogeneous group of hydrated magnesium silicate minerals that have in common a tendency to separate into fibers (Committee on Nonoccupational Health Risks 1984). Asbestos fibers have great tensile strength, heat resistance, and acid resistance, varieties are also flexible (American Thoracic Society 2004).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aberle D, Balmes JR (1991) Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases. Clin Chest 12:115–131
American Thoracic Society (2004) Diagnosis and initial management of non-malignant diseases related to asbestos. Am J Respir Crit Care Med 170:691–715
Berry G (1981) Mortality of workers certified by pneumoconiosis medical panels as having asbestosis. Br J Ind Med 38:130–137
Boutin C et al. (1994) Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74:2460–2467
Brownson T (1998) Current and historical American asbestos regulations. Monaldi Arch Chest Dis 53:181–185
Cleemput J van et al. (2001) Surface of localized pleural plaques quantitated by computed tomography screening. No relation with cumulative asbestos exposure and no effect on lung function. Am J Respir Crit Care Med 163:705–710
Committee on Nonoccupational Health Risks (1984) Asbestiform fibers: nonoccupational health risks. Committee on Nonoccupational Health Risks of Asbestiform Fibers, Board of Toxicology and Environmental Health Hazards, National Research Council. National Academics Press, Washington DC, pp 24–29
Connelly RR et al. (1987) Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78:1053–1060
Copley SJ et al. (2001) Functional consequences of pleural disease evaluated with chest radiography and CT. Radiology 220:237–243
Copley SJ et al. (2007) Asbestos-induced and smoking-related disease: apportioning pulmonary function deficit by using thin-section CT. Radiology 242:258–266
Cugell DW, Kamp DW (2004) Asbestos and the pleura: a review. Chest 125:1103–1117
Das M et al. (2007) Asbestos surveillance program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high risk individuals using low-dose multidetector-row CT. Eur Radiol 17:1193–1199
De Pangher MV et al. (1993) Prognostic factors of malignant pleural mesothelioma of the pleura. Cancer 72:410–417
Eibel R et al. (2003) The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma. Curr Opion Oncol 15:131–138
Epler GR et al. (1982) Prevalence and incidence of benign asbestos pleural effusion in a working population. JAMA 247:617–622
Flehinger BJ, Kimmel M, Melamed MR (1992) Survival from early lung cancer: implications for screening. Chest 101:1013–1018
Fontana RS et al. (1986) Lung cancer screening: the Mayo program. J Occup Med 28:746–750
Goldberg M, Luce D (2005) Can exposure to very low levels of asbestos induce pleural mesothelioma? Am J Respir Crit Care Med 172:939–943
Health Effects Institute (1991) Asbestos in public and commercial buildings: a literature review and synsthesis of current knowledge. Health Effects Institute — Asbestos Research, pp 8–10
Henschke CI et al. (1999) Early lung cancer action project: overall design and findings from baseline screening. Lancet 354:99–105
Hering KG et al. (2004) Standardisierte CT/HRCT-Klassifikation der Bundesrepublik Deutschland für arbeits-und umweltbedingte Thoraxerkrankungen. Radiologe 44:500–511
Herndon JE et al. (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723–731
Hillerdal G (1983) Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77:321–343
Hillerdal G et al. (1987) Benign asbestos pleural effusion: 73 exudates in 60 patients. Eur J Respir Dis 71:113–121
Jones RN et al. (1988) The radiographic pleural abnormalities in asbestos exposure: relationship to physiologic abnormalities. J Thorac Imaging 3:57–66
Kamp DW, Weitzman SA (1999) The molecular basis of asbestos induced lung injury. Thorax 54:638–652
Kaneko M et al. (1996) Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201:798–802
Knisely BL et al. (2000) MR imaging of the pleura and chest wall. Magn Reson Imaging Clin N Am 8:125–141
Light RW (1995) Pleural diseases, 3rd edn. Williams & Wilkins, Baltimore, MD, USA
Marom EM et al. (2002) The role of imaging in malignant pleural mesothelioma. Sem Oncol 29:26–35
McDonald JC, McDonald AD (1997) The epidemiology of mesothelioma in historical context. Eur Respir J 9:1932–1942
McGavin CR, Sheers G (1984) Diffuse pleural thickening in asbestos workers: disability and lung function abnormalities. Thorax 39:604–607
McLoud TC (1988) The use of CT in the examination of asbestos-exposed persons. Radiology 169:862–863
Melamed MR et al. (1984) Screening for lung cancer: results of the Memorial Sloan-Kettering study in New York. Chest 86:44–53
Miettinen OS (2000) Screening for lung cancer: can it be cost-effective? CMAJ 162:1431–1436
Mossman BT et al. (1990) Asbestosis: scientific developments and implications for public policy. Science 247:294–301
Mossman BT et al. (2002) SV40, growth factors, and mesothelioma: another piece of the puzzle. Am J Respir Cell Mol Biol 26:167–170
Müller N (1993) Imaging of the pleura [review]. Radiology 186:297–309
Nesbitt JC et al. (1995) Survival of early-stage lung cancer. Ann Thorac Surg 60:466–472
Nowak D et al. (2005). Screening of lung cancer — state of the art. Pneumologie 59:178–191
Ong ST, Vogelzang NJ (1996) Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14:1007–1017
Pass HI et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 13:1564–1573
Peto J et al. (1999) The European mesothelioma epidemic. Br J Cancer 79:666–672
Remy-Jardin M et al. (2004) Asbestos-related pleuropulmonary diseases: evaluation with low-dose four-detector row spiral CT. Radiology 233:182–190
Ren H et al. (1991) Pleural plaques do not predict asbestosis: high-resolution computed tomography and pathology study. Mod Pathol 4:201–209
Roggli VL, Sanders LL (2000) Asbestos content of lung tissue and carcinoma of the lung: a clinicopathologic correlation and mineral fiber analysis of 234 cases. Ann Occup Hyg 44:109–117
Ross RM (2003) The clinical diagnosis of asbestosis in this century requires more than a chest radiograph. Chest 124:1120–1128
Sargent EN et al. (1984) Subpleural fat pads in patients exposed to asbestos: distinction from non-calcified pleural plaques. Radiology 152:273–277
Scherperel A et al. (2006) Soluble mesothelin-related peptides in the diagnosis of malignant mesothelioma. Am J Respir Crit Care Med 173:1155–1160
Schwartz DA et al. (1990) Determinants of restrictive lung function in asbestos-induced pleural fibrosis. J Appl Physiol 68:1932–1937
Senyigit A et al. (2000) Malignant pleural mesothelioma caused by environmental exposure to asbestos in the southeast of turkey: CT findings in 117 patients. Clin Invest Resp 67:615–622
Sider L et al. (1987) Changes on radiographs of wives of workers exposed to asbestos. Radiology 164:723–726
Sone S et al. (1998) Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351:1242–1245
Sugarbaker DJ et al. (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63
Sterman DH et al. (1998) Adenovirus-mediated herpes simplex virus with thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–1092
Strauss GM (1998) Lung cancer screening and randomized population trials. International Conference on Prevention and Early Diagnosis of Lung Cancer, Varese, Italy, December 9–10
Takita H, Dougherthy TJ (1995) Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin Surg Oncol 11:368–371
Tiitola M et al. (2002) Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer 35:17–22
Tossavainen A (2000) International expert meeting on new advances in the radiology and screening of asbestos-related disease. Scand J Work Environ Health 26:449–454
Welch LS (2003) Asbestos claims trust. LitigationDataSource.com
Yankelevitz DF et al. (1999) Small pulmonary nodules: evaluation with repeat CT-preliminary experience. Radiology 212:561–566
Yoshimura A et al. (1999) A pilot study of lung cancer screening with low-dose spiral CT. Europ Respir J 14(Suppl 30)415s–416s
References
American Cancer Society (2005) Statistics 2005. Cancer facts and figures. Available from: URL: http://www.cancer.org Accessed 10/11/05
Bastarrika G, Garcia Velloso MJ, Lozano MD, Montes U, Torre W, Spiteri N, Campo A, Seijo L, Alcaide AB, Pueyo JC, Cano D, Vivas I, Cosin O, Dominguez P, Serra P, Richter JA, Monteuenga L, Zulueta JJ (2005) Early lung cancer detection with spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 171:1378–1383
Carter D, Vazquez M, Flieder DB, Brambilla E, Gazdar A, Noguchi M, Travis WD, Kramer A, Yip R, Yankelevitz DF, Henschke CI, ELCAP and NY-ELCAP Investigators (Submitted) CT screening for lung cancer: comparison of pathologic findings of baseline and annual repeat cancers. Submitted
Chirikos TN, Hazelton T, Tockman M et al. (2002) Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 121:1507–1514
Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, Heindel W (2002) Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 222:773–781
Finnish Institute of Occupational Health (2000) Finland National Screening Seminar, Helsinki, Finland, Feb 10, 2000
Flehinger BJ, Kimmel M, Melamed MR (1992) Survival from early lung cancer: implications for screening. Chest 101:1013–1018
Frimat P, Paris C, Letourneux M, Catilina P, Sobaszek A (1999) Screening of diseases associated with asbestos. On-going activities, synthesis [French]. Rev Mal Respir 16(6 Pt 2):1350–1355
Grady D (1999) CAT scan process could cut deaths from lung cancer. Small tumors detected. New York Times, July 9 1999, p 1
Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS et al. (1999) Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354:99–105
Henschke CI, Miettinen OS, Yankelevitz DF, Libby D, Smith JP (1994) Radiographic screening for cancer: new paradigm for its scientific basis. Clin Imag 18:16–20
Henschke CI, Naidich DP, Yankelevitz DF, McCauley DI. McGuinness G, Smith JP, Libby DM, Pasmantier MW, Koizumi J, Vazquez M, Flieder D, Altorki NK, Miettinen OS (2001) Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 92:153–159
Henschke CI, Shaham D, Yankelevitz DF, Kramer A, Reeves AP, Vazquez DF, Miettinen OS (2006) CT screening for lung cancer: significance of diagnoses in its baseline cycle. Clin Imag 30:11–15
Henschke CI, Wisnivesky JP, Yankelevitz DF, Miettinen OS (2003) Screen-diagnosed small Stage I cancers of the lung: genuineness and curability. Lung Cancer 39:327–330
Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS (2002) CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR 178:1053–1057
Henschke CI, Yankelevitz DF, Naidich D, McCauley DI, McGuinness G, Libby DM, Smith JP, Pasmantier MW, Miettinen OS (2004) CT screening for lung cancer: suspiciousness of nodules at baseline according to size. Radiology 231:164–168
Henschke CI, Yankelevitz DF, Smith JP, Libby D, Pasmantier MW, McCauley DI, McGuinness G, Naidich DP, Farooqi A, Vazquez M, Miettinen OS (2004) CT screening for lung cancer: assessing a regimen’s diagnostic performance. Clin Imag 28:317–321
Henschke CI, Yankelevitz DF, Smith JP, Miettinen OS (2002) Screening for lung cancer: the Early Lung Cancer Action approach. Lung Cancer 35:143–148
Henschke CI, Yankelevitz DF, Smith JP, Miettinen OS (2002) The use of spiral CT in lung cancer screening. In: DeVita VT, Hellman S, Rosenberg SA (eds) Progress in oncology 2002. Jones and Barlett, Sudbury MA
Henschke CI, Yip R, Yankelevitz DF, Miettinen OS (2005) Computed tomography screening for lung cancer: prospects of surviving competing causes of death. Submitted (Abstract presented at ASCO 2005)
Hill AB (1990) Suspended judgment. Memories of the British Streptomycin Trial in Tuberculosis. The first randomized clinical trial. Control Clin Trials 11:77–79
I-ELCAP (1999) International Conferences on Screening for Lung Cancer. Consensus statements of 1st to 13th Conference. (Website: http://www.IELCAP.org)
I-ELCAP (2005) The I-ELCAP Investigators. CT Screening for lung cancer: individualizing the benefit of screening. Submitted (Abstract presented at ASCO 2005)
I-ELCAP (2006) I-ELCAP Investigators. CT screening for lung cancer: the relationship of disease stage to tumor size. Arch Int Med. In press
Inoue K, Sato M, Fujimura S, Sakurada A, Usuda K, Kondo T, Tanita T, Handa M, Saito Y, Sagawa M (1998) Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. Jpn J Thorac Cardiovasc Surg 116:407–411
Jackson VP (2002) Screening mammography: controversies and headlines. Radiology 225:323–326
Koskinen K, Rinne JP, Zitting A, Tossavainen A, Kivekas J, Reijula K, Roto P, Huuskonen MS (1996) Screening for asbestos-induced diseases in Finland. Am J Ind Med 30(3):241–251
Kostis WJ, Reeves AP, Yankelevitz DF, Henschke CI (2003) Three-dimensional segmentation and growth-rate estimation of small pulmonary nodules in helical CT images. IEEE Trans Med Imag 22:1259–1274
Kostis WJ, Yankelevitz DF, Reeves AP, Fluture SC, Henschke CI (2004) Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. Radiology 231:446–452
Mahadevia PJ, Fleisher LA, Frick K et al. (2003) Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289:313–322
Marshall D, Simpson KN, Earle C et al. (2001a) Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 32:227–236
Marshall D, Simpson KN, Earle C et al. (2001b) Economic decision analysis model of screening for lung cancer. Eur J Cancer 37:1759–1767
Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF (2002a) Mammographic screening: no reliable supporting evidence? Lancet 359:404–405
Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF (2002b) Mammographic screening: No reliable supporting evidence? http://www.lancet.com Feb 2, 2002
Minniti S, Valentini M, Pozzi Mucelli R (2005) Low-dose helical chest CT in asbestos-exposed workers in the Veneto Region: preliminary results. Radiol Med (Torino) 110:317–324
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710–1717
Muravov OI, Kaye WE, Lewin M, Berkowitz Z, Lybarger JA, Campolucci SS, Parker JE (2005) The usefulness of computed tomography in detecting asbestos-related pleural abnormalities in people who had indeterminate chest radiographs: the Libby, MT, experience. Int J Hyg Environ Health 208:87–99
Shaham D, Breuer R, Coppel L et al. (In press) Hadassah Early Lung Cancer Action Project. Findings on baseline and annual repeat screening of an I-ELCAP study. Clin Lung Cancer
Sobue T, Suzuki R, Matsuda M, Kuroishi T, Ikeda S, Naruke T (1992) Survival for clinical stage I lung cancer not surgically treated. Cancer 69:685–692
Sone S, Li F, Yang Z-G, Honda T, Maruyama Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M, Yamanda T (2001) Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 84:25–32
Sone S, Takahima S, Li F, Yang Z et al. (1998) Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351:1242–1245
Straif K, Silverstein M (1997) Comparison of U.S. Occupational Safety and Health Administration standards and German Berufsgenossenschaften Guidelines for Preventive Occupational Health Examinations. Am J Ind Med 31(4):373–380
Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Augenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC (2002) Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 165:508–513
Tiitola M, Kivisaari L, Huuskonen MS, Mattson K, Koskinen H, Lehtola H, Zitting A, Vehmas T (2002) Computed tomography screening for lung cancer in asbestosexposed workers. Lung Cancer 35:17–22
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
Vazquez M, Flieder D, Travis W, Carter D, Yankelevitz D, Miettinen OS, Henschke CI (2003) Early Lung Cancer Action Project Pathology Protocol. Lung Cancer 39:231–232
Wisnivesky JP, Mushlin A, Sicherman N, Henschke CI (2003) Cost-effectiveness of baseline low-dose CT screening for lung cancer: preliminary results. Chest 124:614–621
Yankelevitz DF, Gupta R, Zhao B, Henschke CI (1999) Repeat CT scanning for evaluation of small pulmonary nodules: preliminary results. Radiology 212:561–566
Yankelevitz DF, Reeves A, Kostis W, Zhao B, Henschke CI (2000) Determination of malignancy in small pulmonary nodules based on volumetrically determined growth rates: preliminary results. Radiology 217:251–256
References
Beigelman-Aubry C, Hill C, Grenier PA (2007) Management of an incidentally discovered pulmonary nodule. Eur Radiol 17:449–466
Buck AK, Hetzel M, Schirrmeister H, Halter G, Moller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN (2005) Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 32(5):525–533
Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ (2006) Characterization of the solitary pulmonary nodule: 18F-FDG PET versus noduleenhancement CT AJR Am J Roentgenol 187(5):1361–1367
Devaraj A, Cook GJR, Hansell DM (2007) PET/CT in nonsmall cell lung cancer staging-promises and problems. Clin Radiol 62(2):97–108
Erasmus JJ, McAdams HP, Connolly JE (2000a) Solitary pulmonary nodules. Part II. Evaluation of the indeterminate nodule. RadioGraphics 20:59–66
Erasmus JJ, Connolly JE, McAdams HP, Roggli VL (2000b) Solitary pulmonary nodules. Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 20:43–58
Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ (2006) [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6:51
Grewal RG, Austin JH (1994) CT demonstration of calcification in carcinoma of the lung. J Comput Assist Tomogr 18:867–871
Guckel C, Schnabel K, Deimling M, Steinbrich W (1996) Solitary pulmonary nodules: MR evaluation of enhancement patterns with contrast-enhanced dynamic snapshot gradient-echo imaging. Radiology 200:681–686
Herder GJ, Golding RP, Hoekstra OS et al. (2004) The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 31:1231–1236
Hittmair K, Eckersberger F, Klepetko W, Helbich T, Herold CJ (1995) Evaluation of solitary pulmonary nodules with dynamic contrast-enhanced MR imaging—a promising technique. Magn Reson Imaging 13:923–933
Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 8(7):2109–2115
Jennings SG, Winer-Muram HT, Tarver RD, Farber MO (2004) Lung tumor growth: assessment with CT-comparison of diameter and cross-sectional area with volume measurements. Radiology 231:866–871
Jeong YJ, Lee KS, Jeong SY et al. (2005) Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. Radiology 237:675–683
Kim JH, Kim HJ, Lee KH, Kim KH, Lee HL (2004) Solitary pulmonary nodules: a comparative study evaluated with contrast-enhanced dynamic MR imaging and CT. J Comput Assist Tomogr 28:766–775
Kui M, Templeton PA, White CS, Cai ZL, Bai YX, Cai YQ (1996) Evaluation of the air bronchogram sign on CT in solitary pulmonary lesions. J Comput Assist Tomogr 20:983–986
Lee KS, Jeong YJ, Han J, Kim BT, Kim H, Kwon OJ (2004) T1 non-small cell lung cancer: imaging and histopathologic findings and their prognostic implications. RadioGraphics 24:1617–1636
Lowe VJ, Fletcher JW, Gobar L et al. (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075–1084
Mahoney MC, Shipley RT, Corcoran HL, Dickson BA (1990) CT demonstration of calcification in carcinoma of the lung. AJR Am J Roentgenol 154:255–258
Marten K, Rummeny EJ, Engelke C (2005) Computer-aided diagnosis and volumetry of pulmonary nodules: current concepts and future perspectives. Rofo 177:188–196
Mineura K, Yasuda T, Kowada M et al. (1986) Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurol Res 8:164–168
Munden RF, Hess KR (2001) “Ditzels” on chest CT: urvey of members of the Society of Thoracic Radiology. AJR Am J Roentgenol 176:1363–1369
Muram TM, Aisen A (2003) Fatty metastatic lesions in 2 patients with renal clear-cell carcinoma. J Comput Assist Tomogr 27:869–870
Ohno Y, Hatabu H, Takenaka D, Adachi S, Kono M, Sugimura K (2002) Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. Radiology 224:503–511
Schaefer JF, Vollmar J, Schick F et al. (2004) Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions. Radiology 232:544–553
Swensen SJ (2000) Functional CT: lung nodule evaluation. Radiographics 20:1178–1181
Swensen SJ, Viggiano RW, Midthun DE et al. (2000) Lung nodule enhancement at CT: multicenter study. Radiology 214:73–80
Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N (2002) Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 95:835–842
Winer-Muram HT (2006) The solitary pulmonary nodule. Radiology 239:34–49
Woodring JH, Fried AM, Chuang VP (1980) Solitary cavities of the lung: diagnostic implications of cavity wall thickness. AJR Am J Roentgenol 135:1269–1271
Yi CA, Lee KS, Kim EA et al. (2004) Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233:191–199
Yi CA, Lee KS, Kim B-T et al. (2006) Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47:443–450
Yoon HE, Fukuhara K, Michiura T et al. (2005) Pulmonary nodules 10 mm or less in diameter with ground-glass opacity component detected by high-resolution computed tomography have a high possibility of malignancy. Jpn J Thorac Cardiovasc Surg 53:22–28
Zhang M, Kono M (1997) Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT. Radiology 205:471–478
Zwirewich CV, Vedal S, Miller RR, Muller NL (1991) Solitary pulmonary nodule: high-resolution CT and radiologicpathologic correlation. Radiology 179:469–476
References
Achiron R, Lipitz S, Sivan E et al. (1995a) Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound Obstet Gynecol 6(2):116–120
Achiron R, Lipitz S, Sivan E et al. (1995b) Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 14(9):685–688
ACOG (2001) ACOG committee opinion. Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 73(1):77–79
ACOG (2002) ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 39, October 2002. Selective estrogen receptor modulators. Obstet Gynecol 100(4):835–843
Althuis MD, Sexton M, Langenberg P et al. (2000) Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study. Cancer 89(4):800–810
Andersson M, Storm HH, Mouridsen HAT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83(14):1013–1017
Ascher SM, Johnson JC, Barnes WA et al. (1996) MR imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 200(1):105–110
Ascher SM, Imaoka I, Lage JM (2000) Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 214(1):29–38
Ascher SM, Johnson J, Zeman RK, Patt RH (1995) Uterine changes in women receiving tamoxifen therapy: prospective comparison of MR imaging and transvaginal sonography with pathologic correlation (abstr). Radiology 197(P):353–354
Assikis VJ, Neven P, Jordan VC et al. (1996) A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A(9):1464–7146
Atri M, Nazarnia S, Aldis AE et al. (1994) Transvaginal US appearance of endometrial abnormalities. Radiographics 14(3):483–492
Baldwin MT, Dudiak KM, Gorman B et al. (1999) Focal intracavitary masses recognized with the hyperechoic line sign at endovaginal US and characterized with hysterosonography. Radiographics 19(4):927–935
Barakat RR (1996) Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 39(3):629–640
Barakat RR, Gilewski TA, Almadrones L et al. (2000) Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18(20):3459–3463
Bergman L, Beelen ML, Gallee MP et al. (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356(9233):881–887
Berliere M, Charles A, Galant C et al. (1998) Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91(1):40–44
Bourne TH, Lawton F, Leather A et al. (1994) Use of intracavity saline instillation and transvaginal ultrasonography to detect tamoxifen-associated endometrial polyps. Ultrasound Obstet Gynecol 4(1):73–75
Cardosi RJ, Fiorica JV (2000) Surveillance of the endometrium in tamoxifen treated women. Curr Opin Obstet Gynecol 12(1):27–31
Cecchini S, Ciatto S, Bonardi R et al. (1996) Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 60(3):409–411
Cheng WF, Lin HH, Torng PL et al. (1997) Comparison of endometrial changes among symptomatic tamoxifentreated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 66(2):233–237
Cohen CJ (1997) Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Semin Oncol 24(1 Suppl 1):S1-55–S1-64
Cohen I, Rosen DJ, Tepper R et al. (1993) Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 12(5):275–280
Cohen I, Altaras MM, Shapira J et al. (1994a) Postmenopausal tamoxifen treatment and endometrial pathology. Obstet Gynecol Surv 49(12):823–829
Cohen I, Rosen DJ, Shapira J et al. (1994b) Endometrial changes with tamoxifen: comparison between tamoxifentreated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52(2):185–190
Cohen I, Beyth Y, Tepper R et al. (1995) Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 58(1):86–91
Cohen I, Bernheim J, Azaria R et al. (1999) Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 75(1):136–141
Cohen I (2004) Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94(2):256–266
Corley D, Rowe J, Curtis MT et al. (1992) Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 79(1):111–116
Cullinan JA, Fleischer AC, Kepple DM et al. (1995) Sonohysterography: a technique for endometrial evaluation. Radiographics 15(3):501–514; discussion 515–516
Curtis RE, Boice JD Jr, Shriner DA et al. (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88(12):832–834
De Muylder X, Neven P, De Somer M et al. (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36(2):127–130
Deligdisch L, Kalir T, Cohen CJ et al. (2000) Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78(2):181–186
DelMaschio A, Vanzulli A, Sironi S et al. (1993) Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. AJR Am J Roentgenol 160(3):533–538
Develioglu OH, Omak M, Bilgin T et al. (2004) The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 93(2):328–335
Dilts PV Jr, Hopkins MP, Chang AE et al. (1992) Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 166(1 Pt 1):167–168
Dubinsky TJ, Parvey HR, Maklad N (1997) The role of transvaginal sonography and endometrial biopsy in the evaluation of peri-and postmenopausal bleeding. AJR Am J Roentgenol 169(1):145–149
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group (1998) Lancet 351(9114):1451–146
Ferrazzi E, Leone FP (2004) Investigating abnormal bleeding on HRT or tamoxifen: the role of ultrasonography. Best Pract Res Clin Obstet Gynaecol 18(1):145–156
Fisher B, Costantino JP, Redmond CK et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527–537
Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388
Fisher B, Jeong JH, Dignam J et al. (2001) Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 30):62–66
Fong K, Kung R, Lytwyn A et al. (2001) Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 220(3):765–773
Fong K, Causer P, Atri M et al. (2003) Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 23(1):137–150; discussion 151–155
Forbes JF (1997) The control of breast cancer: the role of tamoxifen. Semin Oncol 24(1 Suppl 1):S1-5–S1-19
Fornander T, Rutqvist LE, Cedermark B et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1(8630):117–120
Franchi M, Ghezzi F, Donadello N et al. (1999) Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 93(6):1004–1008
Freedman AN, Graubard BI, Rao SR et al. (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95(7):526–532
Fung MF, Reid A, Faught W et al. (2003) Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91(1):154–159
Gal D, Kopel S, Bashevkin M et al. (1991) Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer-preliminary report. Gynecol Oncol 42(2):120–123
Gerber B, Krause A, Muller H et al. (2000) Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18(20):3464–3470
Goldstein SR, Nachtigall M, Snyder JR et al. (1990) Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 163(1 Pt 1):119–123
Goldstein SR (1994) Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170(2):447–451
Gompel C SS (1994) Pathology in gynecology and obstetrics. The corpus uteri, ed. Gompel C SS. Vol. 4th edition. Lippincott, Philadelphia, pp 163–283
Granberg S, Wikland M, Karlsson B et al. (1991) Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 164(1 Pt 1):47–52
Hann LE, Giess CS, Bach AM et al. (1997) Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol 168(3):657–661
Hann LE, Kim CM, Gonen M et al. (2003) Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. J Ultrasound Med 22(11):1173–1179
Hricak H, Stern JL, Fisher MR et al. (1987) Endometrial carcinoma staging by MR imaging. Radiology 162(2):297–305
Hricak H, Hamm B, Semelka RC et al. (1991) Carcinoma of the uterus: use of gadopentetate dimeglumine in MR imaging. Radiology 181(1):95–106
Hricak H, Finck S, Honda G et al. (1992) MR imaging in the evaluation of benign uterine masses: value of gadopentetate dimeglumine-enhanced T1-weighted images. AJR Am J Roentgenol 158(5):1043–1050
Hulka CA, Hall DA (1993) Endometrial abnormalities associated with tamoxifen therapy for breast cancer: sonographic and pathologic correlation. AJR Am J Roentgenol 160(4):809–812
Ismail SM (1994) Pathology of endometrium treated with tamoxifen. J Clin Pathol 47(9):827–833
IARC (1996) International Agency for Research on Cancer Consensus report. Mechanisms of fibre carcinogenesis. IARC Sci Publ 140):1–9
Ito K, Matsumoto T, Nakada T et al. (1994) Assessing myometrial invasion by endometrial carcinoma with dynamic MRI. J Comput Assist Tomogr 18(1):77–86
Ito T, Katagiri C, Murata Y et al. (2001) Indication for histological examination of endometrium in breast carcinoma patients receiving tamoxifen therapy. J Obstet Gynaecol Res 27(3):141–145
Jaiyesimi IA, Buzdar AU, Decker DA et al. (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13(2):513–529
Karlsson B, Granberg S, Wikland M et al. (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding — a Nordic multicenter study. Am J Obstet Gynecol 172(5):1488–1494
Kedar RP, Bourne TH, Powles TJ et al. (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343(8909):1318–1321
Kolata G FL (1998) Drugs to fight breast cancer near approval. The New York Times p A18
Kurman RJ NH (1994) Endometrial hyperplasia and related cellular changes. In: Blausteins’s pathology of the female genital tract, 4th edn. Springer, Berlin Heidelberg New York, pp 411–437
Lahti E, Blanco G, Kauppila A et al. (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81(5 Pt 1):660–664
Laifer-Narin SL, Ragavendra N, Lu DS et al. (1999) Transvaginal saline hysterosonography: characteristics distinguishing malignant and various benign conditions. AJR Am J Roentgenol 172(6):1513–1520
Langer RD, Pierce JJ, O’Hanlan KA et al. (1997) Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N Engl J Med 337(25):1792–1798
Lasset C, Bonadona V, Mignotte H et al. (2001) Tamoxifen and risk of endometrial cancer. Lancet 357(9249):66–67
Levine D, Gosink BB, Johnson LA (1995) Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology 197(3):603–608
Lev-Toaff AS (1996) Sonohysterography: evaluation of endometrial and myometrial abnormalities. Semin Roentgenol 31(4):288–298
Lipson SA, Hricak H (1996) MR imaging of the female pelvis. Radiol Clin North Am 34(6):1157–1182
Love CD, Muir BB, Scrimgeour JB et al. (1999) Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17(7):2050–2054
Lumsden MA, West CP, Hillier H et al. (1989) Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil Steril 52(6):924–929
Machado F, Rodriguez JR, Leon JP et al. (2005) Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur J Gynaecol Oncol 26(3):257–265
Magriples U, Naftolin F, Schwartz PE et al. (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11(3):485–490
Marconi D, Exacoustos C, Cangi B et al. (1997) Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc 4(3):331–339
McGonigle KF, Shaw SL, Vasilev SA et al. (1998) Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178(6):1145–1150
Mignotte H, Lasset C, Bonadona V et al. (1998) Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer 76(3):325–330
Mourits MJ, Van der Zee AG, Willemse PH et al. (1999) Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 73(1):21–26
Mourits MJ, De Vries EG, Willemse PH et al. (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97(5 Pt 2):855–866
Narod SA, Pal T, Graham T et al. (2001) Tamoxifen and risk of endometrial cancer. Lancet 357(9249):65–66; author reply 67
Nayfield SG, Karp JE, Ford LG et al. (1991) Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83(20):1450–1459
Neven P, De Muylder X, Van Belle Y et al. (1990) Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 35(2–3):235–238
Neven P, De Muylder X, Van Belle Y et al. (1998) Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351(9095):36
Neven P, Vergote I (1998) Should tamoxifen users be screened for endometrial lesions? Lancet 351(9097):155–157
Neven P, Vernaeve H (2000) Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 22(1):1–11
Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609–1618
Peters-Engl C, Frank W, Danmayr E et al. (1999) Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 54(3):255–260
Ragaz J, Coldman A (1998) Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol 16(6):2018–2024
Reinhold C GB, Ascher SM (1997) Uterus and cervix. MRI of the abdomen and pelvis: a text atlas, ed. Semelka RC AS, Reinhold C, New York: Wiley-Liss. 585–660
Renard F, Vosse M, Scagnol I et al. (2002) Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. Case report. Eur J Gynaecol Oncol 23(1):25–28
Schlesinger C, Kamoi S, Ascher SM et al. (1998) Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol 17(4):302–311
Shipley CF III, Simmons CL, Nelson GH (1994) Comparison of transvaginal sonography with endometrial biopsy in asymptomatic postmenopausal women. J Ultrasound Med 13(2):99–104
Silva A AS, Ascher S, Reinhold C (1998) Magnetic resonance imaging versus ultrasound in the assessment of benign uterine lesions. Radiology of the femal pelvic organs, ed. E L, Berlin, Heidelberg, New York: Springer-Verlag. pp 43–67
Sinawat S (2002) Prevention of endometrial cancer in breast cancer patients taking tamoxifen: the gynecologists’ role. Asian Pac J Cancer Prev 3(3):251–255
Sladkevicius P, Valentin L, Marsal K (1994) Endometrial thickness and Doppler velocimetry of the uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study. Am J Obstet Gynecol 171(3):722–728
Suh-Burgmann EJ, Goodman A (1999) Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 131(2):127–135
Tepper R, Beyth Y, Altaras MM et al. (1997) Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 64(3):386–391
Ugwumadu AH, Bower D, Ho PK (1993) Tamoxifen induced adenomyosis and adenomyomatous endometrial polyp. Br J Obstet Gynaecol 100(4):386–388
Uziely B, Lewin A, Brufman G et al. (1993) The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 26(1):101–105
van Leeuwen FE, Benraadt J, Coebergh JW et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343(8895):448–452
Varras M, Polyzos D, Akrivis C (2003) Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 24(3–4):258–268
Vosse M, Renard F, Coibion M et al. (2002) Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 101(1):58–63
Wickerham DL, Fisher B, Wolmark N et al. (2002) Association of tamoxifen and uterine sarcoma. J Clin Oncol 20(11):2758–2760
Wilder JL, Shajahan S, Khattar NH et al. (2004) Tamoxifenassociated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogenalpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol 92(2):553–558
Wolman I, Jaffa AJ, Hartoov J et al. (1996) Sensitivity and specificity of sonohysterography for the evaluation of the uterine cavity in perimenopausal patients. J Ultrasound Med 15(4):285–288
www.astrazeneca.com
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Eibel, R. et al. (2008). Exogenous Exposure: Occupation and Environment. In: Reiser, M.F., van Kaick, G., Fink, C., Schoenberg, S.O. (eds) Screening and Preventive Diagnosis with Radiological Imaging. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-49831-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-49831-5_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23553-8
Online ISBN: 978-3-540-49831-5
eBook Packages: MedicineMedicine (R0)